Effects of c-Met on proliferation of triple negative breast cancer and sensitivity to doxorubicin
DENG Zhi-ping1,2, LIAO He-he1, WANG Zhou-quan1, YANG Bo1, SONG Zhang-jun1, YAO Jun-tao1, REN Hong1, ZHANG Ming-xin3
1. The Second Department of Thoracic Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China;
2. Department of Breast Disease, Tumor Hospital of Shaanxi, Xi'an 710061, China;
3. Tangdu Hospital of The Fourth Military Medical University, Xi'an 710000, China
AIM: To investigate the effects of c-Met on the proliferation and the sensitivity to chemotherapeutic drugs of triple negative breast cancer cells. METHODS: Doxorubicin-resistant cells (MDA-MB-231/ADR) were established. The expression of c-Met at mRNA and protein levels in the MDA-MB-231/ADR cells and parental MDA-MB-231 cells was detected by real-time PCR and Western blotting. c-Met siRNA and plasmid or AKT siRNA were transfected into the cancer cells. The cell proliferation and the sensitivity to doxorubicin were determined by MTT assay. RESULTS: The expression of c-Met at mRNA and protein levels in MDA-MB-231/ADR cells was significantly higher than that in parental MDA-MB-231 cells. Transfection with pBABE-puro TPR-MET plasmid into the MDA-MB-231 cells induced cell proliferation and resistance to doxorubicin. Meanwhile, inhibition of c-Met in the MDA-MB-231/ADR cells by siRNA reversed the doxorubicin-resistance. In addition, over-expression of c-Met led to higher phosphorylation level of AKT, which was involved in the effects of c-Met on the MDA-MB-231 cell proliferation and doxorubicin-resistance. CONCLUSION: c-Met may have the potential as a therapeutic target in the treatment of triple negative breast cancer.
邓智平, 廖和和, 王周权, 杨波, 宋张骏, 姚俊涛, 任宏, 张明鑫. c-Met对三阴性乳腺癌细胞增殖及阿霉素耐药性的影响[J]. 中国病理生理杂志, 2015, 31(3): 447-451.
DENG Zhi-ping, LIAO He-he, WANG Zhou-quan, YANG Bo, SONG Zhang-jun, YAO Jun-tao, REN Hong, ZHANG Ming-xin. Effects of c-Met on proliferation of triple negative breast cancer and sensitivity to doxorubicin. Chin J Pathophysiol, 2015, 31(3): 447-451.
Poage GM, Hartman ZC, Brown PH. Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy[J]. Cell Cycle, 2013, 12(17):2705-2706.
[2]
Crown J, O'Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer[J]. Ann Oncol, 2012, 23(Suppl 6):vi56-vi65.
[3]
Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in can-cer therapy[J]. J Clin Oncol, 2012, 30(26):3287-3296.
[4]
Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation[J]. Nat Genet, 2005, 37(10):1047-1054.
[5]
Fang Y, Shen H, Cao Y, et al. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells[J]. Braz J Med Biol Res, 2014, 47(1):60-69.
[6]
Bao L, Hazari S, Mehra S, et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298[J]. Am J Pathol, 2012, 180(6):2490-2503.
[7]
Usatyuk PV, Fu P, Mohan V, et al. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells[J]. J Biol Chem, 2014, 289(19):13476-13491.
[8]
Inanc M, Ozkan M, Karaca H, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer[J]. Med Oncol, 2014, 31(1):801.
[9]
Raghav KP, Wang W, Liu S, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes[J]. Clin Cancer Res, 2012, 18(8):2269-2277.
[10]
Gastaldi S, Comoglio PM, Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for?[J]. Breast Cancer Res, 2010, 12(4):208.
Que W, Chen J. Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro[J]. Mol Med Rep, 2011, 4(2):343-349.
[13]
Shattuck DL, Miller JK, Carraway KL 3rd, et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells[J]. Cancer Res, 2008, 68(5):1471-1477.
